Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 981 to 990 of 2636 total matches.
Bone Densitometry
The Medical Letter on Drugs and Therapeutics • Nov 22, 1996 (Issue 988)
and treatment of osteoporosis (Medical Letter, 38:1, 1996) has been accompanied by widespread availability ...
Use of alendronate (Fosamax), estrogen and other drugs for prevention and treatment of osteoporosis (Medical Letter, 38:1, 1996) has been accompanied by widespread availability of bone density screening tests, not only in doctors offices and hospitals, but even in retail stores. Bone densitometry provides a quantitative measurement of bone mineralization that can be used to predict the risk of osteoporotic fractures.
Sibutramine for Obesity
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
on a restricted calorie diet found that patients taking a placebo
lost 0.9 kg and those taking 1-, 5-, 10-, 15 ...
Sibutramine hydrochlorid monohydreate (Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency (DEA) as a schedule IV controlled substance.
Docosanol Cream (Abreva) for Recurrent Herpes Labialis
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000 (Issue 1092)
(SmithKline Beecham) 1% cream (1.5g) q2h during the day 27.17
* Retail price for one tube in the smallest ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010 (Issue 1351)
for treatment of cervical
dystonia. Botox is also approved for treatment of blepharospasm.
1
CERVICAL ...
The FDA has approved incobotulinumtoxinA (Xeomin –
Merz) for treatment of cervical dystonia and blepharospasm
in adults. It has been commercially available
in Germany since 2005. Several formulations of
botulinum toxin type A (Botox; Dysport) and type B
(Myobloc) are already marketed for treatment of cervical
dystonia. Botox is also approved for treatment of blepharospasm.
Mifepristone (Korlym) for Cushing's Syndrome
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012 (Issue 1392)
to glucocorticoid receptors
and, to a lesser extent, androgen receptors.
Table 1. Pharmacology
Formulation 300-mg ...
The FDA has approved the antiprogestin mifepristone
(Korlym – Corcept Therapeutics) for control of hyperglycemia
secondary to hypercortisolism in adults with
endogenous Cushing’s syndrome who have type 2 diabetes/
glucose intolerance and have not responded to,
or are not candidates for, surgery. Formerly known as
RU 486, mifepristone is also available in a lower
strength as Mifeprex for use in terminating an early
intrauterine pregnancy.
A New Scorpion Antivenom
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
17,000 scorpion
stings are reported every year in the US.1 Arizona
alone reports more than 10,000 ...
Anascorp (Rare Disease Therapeutics), an intravenously
administered antivenom derived from horse
serum, has been approved by the FDA for treatment of
clinical signs of scorpion envenomation.
Renal Sympathetic Denervation for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012 (Issue 1394)
Publication
CLINICAL STUDIES — The first study of the
cathether-based procedure (Symplicity HTN-1)
included ...
Renal sympathetic denervation is under investigation as
a therapeutic option for hypertension that has not
responded to ≥3 antihypertensive drugs (resistant
hypertension).
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
% of patients with
Parkinson’s disease.1 Low doses of clozapine
(Clozaril, and others) have been effective ...
The FDA has approved the atypical antipsychotic
pimavanserin (Nuplazid – Acadia) for treatment
of hallucinations and delusions associated with
Parkinson's disease. It is the first drug to be approved
in the US for this indication.
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
diabetes and established cardiovascular
disease (CVD) or multiple cardiovascular risk factors,1,2
has now ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease
(CVD) or multiple cardiovascular risk factors, has
now been approved for a third indication: to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in patients with heart failure
with reduced ejection fraction (with or without
type 2 diabetes). It is the first SGLT2 inhibitor to...
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
years old.1 The original formulation
of Comirnaty (30 mcg/0.3 mL) is FDA-licensed for
use in persons ...
The FDA has issued an Emergency Use Authorization
(EUA) for a lower-strength (10 mcg/0.2 mL) formulation
of the mRNA-based COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) for use
in children 5-11 years old. The original formulation
of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for
use in persons ≥16 years old and available under an
EUA for use in adolescents 12-15 years old.